Cover Image

Prostate- and metastases-directed radiotherapy in de novo low-volume metastatic prostate cancer

Background - The role of radiotherapy in de novo low-volume metastatic prostate cancer (LVmPC) is constantly evolving and still offers considerable potential for further optimization. Rising interest in this topic demands further investigations in this specific patient cohort. We report on clinical...

Full description

Saved in:
Bibliographic Details
Main Authors: Bolten, Jan-Hendrik (Author) , Weykamp, Fabian (Author) , Grott, Christoph A. (Author) , Neugebauer, David (Author) , Wessel, Lars (Author) , Englert, Felix Hermann (Author) , Valentini, Justus (Author) , Görtz, Magdalena (Author) , Zschäbitz, Stefanie (Author) , Huber, Johannes (Author) , Winter, Erik (Author) , Debus, Jürgen (Author) , Liermann, Jakob (Author)
Format: Article (Journal)
Language:English
Published: January 2026
In: Clinical and translational radiation oncology
Year: 2026, Volume: 56, Pages: 1-7
ISSN:2405-6308
DOI:10.1016/j.ctro.2025.101072
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ctro.2025.101072
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2405630825001648
Get full text
Author Notes:Jan-Hendrik Bolten, Fabian Weykamp, Christoph Grott, David Neugebauer, Lars Wessel, Felix H. Englert, Justus Valentini, Magdalena Goertz, Stephanie Zschaebitz, Johannes Huber, Erik Winter, Juergen Debus, Jakob Liermann
Description
Summary:Background - The role of radiotherapy in de novo low-volume metastatic prostate cancer (LVmPC) is constantly evolving and still offers considerable potential for further optimization. Rising interest in this topic demands further investigations in this specific patient cohort. We report on clinical outcomes and toxicity of combined prostate-directed (PDRT) and metastasis-directed radiotherapy (MDRT) with ablative dose concepts in patients with de novo LVmPC. - Methods - We retrospectively analyzed 21 patients with LVmPC treated with PDRT plus MDRT between 2018 and 2025 in addition to systemic treatment. Staging was performed with PSMA-PET/CT imaging (n = 19/21). Radiotherapy included high-dose external beam PDRT and MDRT to all detectable bone and nodal metastases. Toxicity was assessed using CTCAE v5.0, IPSS, and EPIC-26 questionnaires. Oncologic outcomes included biochemical recurrence-free survival, PSA response, and time to next-line systemic therapy. - Results - Additional radiotherapy of all tumor sites in LVmPC was well tolerated; no grade ≥ III gastrointestinal or genitourinary toxicity occurred. The most common adverse events were associated with hormonal therapy. Quality of life remained stable or improved in urinary and bowel domains. Undetectable PSA was achieved in 67 % of patients after radiotherapy in addition to systemic therapy. 14 % of the patients developed biochemical recurrence within 40 months after radiotherapy completion. - Conclusion - Combined PDRT and MDRT in addition to standard of care in patients with de novo LVmPC is feasible, well tolerated, and associated with promising biochemical control. Further prospective studies with larger patient cohorts integrating PSMA-PET/CT and other risk stratification factors are warranted to better define which patient subgroups benefit most from additional radiotherapy.
Item Description:Online verfügbar: 14. November 2025, Artikelversion: 19. November 2025
Gesehen am 27.01.2026
Physical Description:Online Resource
ISSN:2405-6308
DOI:10.1016/j.ctro.2025.101072

Similar Items